<?xml version="1.0" encoding="UTF-8"?>
<p id="Par44">Angiotensin II, the main effector molecule in the RAAS, is upregulated in many diseases and is a common treatment target for various cardiovascular disorders
 <sup>
  <xref ref-type="bibr" rid="CR61">61</xref>,
  <xref ref-type="bibr" rid="CR100">100</xref>,
  <xref ref-type="bibr" rid="CR113">113</xref>
 </sup>. ACE2 inactivates angiotensin II by converting angiotensin II to angiotensin (1–7)
 <sup>
  <xref ref-type="bibr" rid="CR61">61</xref>,
  <xref ref-type="bibr" rid="CR100">100</xref>
 </sup>. Cryogenic electron microscopy studies have demonstrated that the S protein of SARS-CoV-2 can directly bind to human ACE2 with a similar or even higher affinity than the binding of the S protein of SARS-CoV to human ACE2 (refs
 <sup>
  <xref ref-type="bibr" rid="CR9">9</xref>–
  <xref ref-type="bibr" rid="CR11">11</xref>
 </sup>). In this context, a study has shown that exogenous administration of recombinant human ACE2 (rhACE2) can prevent SARS-CoV-2 infection by acting as a decoy
 <sup>
  <xref ref-type="bibr" rid="CR114">114</xref>
 </sup>. The investigators demonstrated that clinical-grade rhACE2 can reduce SARS-CoV-2 infection in cell culture and in engineered human blood vessel organoids and kidney organoids
 <sup>
  <xref ref-type="bibr" rid="CR114">114</xref>
 </sup>. Given that rhACE2 has been shown to be protective against various CVDs
 <sup>
  <xref ref-type="bibr" rid="CR61">61</xref>,
  <xref ref-type="bibr" rid="CR115">115</xref>,
  <xref ref-type="bibr" rid="CR116">116</xref>
 </sup>, rhACE2 therapy might be a promising approach to treat patients with COVID-19-related cardiovascular disorders
 <sup>
  <xref ref-type="bibr" rid="CR114">114</xref>
 </sup>.
</p>
